A5083345843- Childhood Cancer Survivors' Quality of Life
- Health Systems, Economic Evaluations, Quality of Life
- Adolescent and Pediatric Healthcare
- Synthesis of Tetrazole Derivatives
- Complementary and Alternative Medicine Studies
- Primary Care and Health Outcomes
- Genetic factors in colorectal cancer
- Innovations in Medical Education
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Healthcare Policy and Management
- Chemotherapy-related skin toxicity
- Cancer Genomics and Diagnostics
- Chronic Myeloid Leukemia Treatments
- Prostate Cancer Treatment and Research
- Pharmaceutical industry and healthcare
- Multiple Sclerosis Research Studies
- Economic and Financial Impacts of Cancer
- Genital Health and Disease
- Acute Lymphoblastic Leukemia research
- Ethics and Legal Issues in Pediatric Healthcare
Partnership for Health Analytic Research
2022-2024
Background: Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Pediatric-onset MS (POMS), defined as onset before 18 years age, estimated to account for 2% 5% population worldwide. Objectives: To conduct literature review focused on healthcare resource utilization and cost well quality-of-life (QOL) outcomes among patients with POMS. Methods: We conducted systematic English-language studies published after September 2010 in MEDLINE Embase...
Background and objective Recent clinical trials have shown improvement in progression-free survival men with metastatic prostate cancer (mPC) treated combination poly-ADP ribose polymerase (PARP) inhibitors (PARPi) novel hormonal therapy (NHT). Regulatory bodies the USA, Canada, Europe, Japan recently approved this for mPC. Common adverse events (AEs) include fatigue, nausea vomiting, anemia. Nuanced AE management guidance these combinations is lacking. The panel was to develop expert...
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Pediatric-onset MS (POMS), defined as onset before 18 years age, estimated to account for 2% 5% population worldwide.
Abstract Background Alternative funding programs (AFPs) seek to reduce plan sponsor costs by excluding specialty drugs from a beneficiary’s coverage and requiring patients obtain medications through alternative sources (typically, the manufacturer’s patient assistance [PAPs]) via an AFP vendor as third-party). Objective To describe patients’ experiences medication access with AFPs, which have not been explored previously. Methods A survey instrument consisting of optional single-...
Alternative funding programs (AFPs) seek to reduce health plan sponsor costs, for example by excluding specialty drugs from a beneficiary's coverage and requiring patients obtain medications through alternative sources (typically, the manufacturer's patient assistance programs) via an AFP vendor as third-party.